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Despite the improved efficacy of peginterferons, the rate of sustained virologic response is suboptimal in cirrhotic 
patients, relative to non-cirrhotic patients. However, the treatment of patients with compensated cirrhosis has recently 
been encouraged by expert panels. Interferon-based therapy may provide additional benefit by reducing the risk of 
hepatocellular carcinoma in cirrhotic patients as suggested in preliminary studies. Results of two ongoing prospective 
studies are awaited to answer the important question of the effectiveness of suppressive interferon therapy, even in the 
absence of sustained virologic response. Given the importance of recurrent HCV following liver transplantation, 
attention has been directed toward the antiviral treatment of patients with advanced liver disease. This approach needs 
to be pursued with caution given the potential morbidity of the therapy. Recently, a low accelerating dosage regimen 
has provided excellent results and is the subject of additional inquiry. 
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1.  Treatment in compensated cirrhosis 
The response to interferon-based therapy for patients 
with compensated cirrhosis due to hepatitis C has been 
evaluated in several trials, both as the focus of prospective 
study, as well as in subgroup (post hoc) analyses of large 
registration trials.  Despite the improved efficacy of 
peginterferons, the sustained virological response (SVR) 
rate is suboptimal in cirrhotic patients, relative to non-
cirrhotic patients.  However, the treatment of patients 
with compensated cirrhosis has recently been encouraged 
by the International Liver Transplant Society Expert Panel 
in 2003 which concluded that patients with relatively 
compensated cirrhosis, defined by a MELD score of 18 or 
less, are acceptable treatment candidates. [1] 
The likelihood of achieving an SVR with interferon-
based therapy in cirrhotic patients can be deduced from 
prior studies which focused upon, or incorporated 
patients with, advanced fibrosis.  Arguably, the most 
important trial on this issue was conducted by Heathcote 
and colleagues in patients with advanced stage fibrosis or 
cirrhosis. [2] Patients were randomized to peginterferon 
α-2a, at one of two doses (90 mcg or 180 mcg weekly), or 
standard interferon.  Two thirds of those entered had 
cirrhosis.  The SVR rate was greatest for those treated with 
peginterferon alpha-2a 180 mcg weekly for 48 weeks 
(30%); this is in comparison to a SVR rate of only 8% in 
those treated with standard, thrice weekly, interferon.  In 
subgroup analysis comparing those with bridging fibrosis 
to those with cirrhosis, there did not appear to be a 
statistically significant difference between the groups in 
terms of achieving an SVR.  The patients infected with 
genotype 1 who received the 180 mcg dose of pegylated 
interferon had a 12% SVR rate, in comparison to 51% non-
type 1 genotypes treated with this dose.   
Further analysis of data from the Heathcote trial 
revealed that treatment was associated with histological 
improvement, especially in the group that experienced an 
SVR.  Comparing the pegylated interferon group (180 
mcg) group to standard interferon, histological 
improvement occurred in 54% and 31% respectively.   
Pertinent to the issue of histological effects of therapy, 
Poynard pooled data retrospectively from 4 large 
randomized controlled trials that included paired 
biopsies. [3] This analysis included data on 3,010 patients 
treated for either 24 or 48 weeks.  Overall, improvement in 
both the inflammatory grade and histologic stage of 
disease were associated with therapy.  Longer duration of 
therapy strengthened this association.  Of the 153 cirrhotic 
patients with SVR included in this analysis, 75 (49%) had 
significant improvement in fibrosis after treatment. 
Interferon-based therapy may provide additional 
benefit by reducing the risk of hepatocellular carcinoma in 
cirrhotic patients as suggested in preliminary studies.  In a 
study among 103 patients with HCV-related cirrhosis, 
those receiving interferon had a lower incidence of 
hepatocellular carcinoma and improved survival after 4 
years. [4]  A reduction in the risk for hepatocellular 
carcinoma in cirrhotic patients was also detected in a 
Japanese trial of patients on interferon monotherapy for a 
median of 3 years. [5]  Therefore, in addition to 
establishing a target for therapeutic efficacy in patients 
with advanced fibrosis, early studies suggest potential 
histological and survival benefits of interferon-based 
treatment.   
Insight into the efficacy of combination therapy with 
pegylated interferon and ribavirin in cirrhotic patients can 
be obtained from the large registration trials for pegylated 
interferon.  In the peginterferon alfa-2b registration trial, 
the 6% of participants that had cirrhosis demonstrated a 
lower SVR rate compared to those study subjects without 
cirrhosis. [6] Cirrhotic patients treated with pegylated 
interferon alfa-2b, 1.5 mcg/kg weekly in plus ribavirin 800 
mg a day for 48 weeks had a 44% SVR; in comparison, 
patients treated with standard interferon alfa-2b, 3 million Int. J. Med. Sci. 2006, 3 
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units three times a week plus ribavirin for 48 weeks had a 
slightly lower response rate of 41%.  In the second 
published pivotal trial of combined therapy with 
pegylated interferon and ribavirin, cirrhotic patients 
treated with peginterferon alfa-2a plus ribavirin for 48 
weeks had SVR rate of 43%, compared to 33% in patients 
treated with standard interferon combined with ribavirin.  
Non-cirrhotic patients enrolled into this study had SVR 
rates of 58% and 46% respectively. [7] 
Results of two ongoing prospective studies are 
awaited to answer an important question that remains; is 
there any benefit of prolonged treatment of patients with 
advanced fibrosis or cirrhosis, even in the absence of SVR?  
The National Institutes of Health sponsored HALT-C trial 
(Hepatitis C Antiviral Long Term Treatment against 
Cirrhosis), is a multicenter study of the potential benefit of 
prolonged peginterferon therapy in mitigating the 
progression of fibrotic liver disease. [8] In this study, 391 
of the 1045 patients enrolled into the initial “lead-in” 
phase had biopsy proven cirrhosis.  Preliminary results 
show that cirrhosis alone impaired response to therapy, 
with lower SVR rates compared to non-cirrhotic patients. 
[9] In the COPILOT study (Colchicine Versus PEG-Intron 
Long Term), enrollees are predominantly cirrhotic 
patients who failed prior treatment. [10] An interim 
analysis suggested a benefit to pegylated interferon 
therapy, over colchicine, in reducing complications 
associated with cirrhosis. Long term outcome data from 
this trial and other suppressive protocols will determine 
the efficacy of such an approach. [11] 
In summary, patients with advanced fibrosis or 
cirrhosis have a lower SVR compared to non-cirrhotic 
patients, even with the latest combination therapy.   
However, existing data support therapy of the patient 
with compensated cirrhosis.  Cirrhotic patients may 
tolerate therapy less well, given the propensity for 
thrombocytopenia and leucopenia, as was seen in the 
three large trials that included cirrhotic patients. [2, 4, 11] 
In practice, growth factors are commonly used to counter 
the treatment related cytopenias.  The use of these agents 
is costly and has not been studied rigorously in a 
randomized controlled format to assess their value and 
impact on efficacy of therapy although they are now 
widely used in patients receiving interferon therapy.  
2.  Treatment of advanced liver disease 
Chronic HCV infection is the leading indication for 
liver transplantation (LT) in the United States and Europe. 
Given the accelerated progression of HCV following LT, 
the observation than higher pre-transplant viral load is 
associated with poorer transplant outcome, and the 
difficulties in treatment of the infection following LT [12], 
it is reasonable to emphasize the importance of pre-
transplant treatment of HCV. The International Liver 
Transplantation Society Expert Panel provided guidelines 
when considering interferon-based treatment in patients 
with HCV-cirrhosis. As seen in Table 1, this group advises 
treatment even in some patients with advanced cirrhosis. 
Table 1. International Liver Transplantation Society Expert 
Panel Consensus Conference proposed guidelines for interferon-
based treatment of patients with cirrhosis [1] 
Consider Treatment  CTP Score  MELD Score 
Strongly consider  ≤7  ≤18 
In select cases  8-11  18-25 
Treatment not advised  >11  >25 
 
Clearly, there are major obstacles toward treatment 
of this group of patients. Since the advent of MELD-based 
allocation, with the associated lessened importance of 
waiting time, those awaiting liver transplant are more ill. 
The resulting poor synthetic function, presence of hepatic 
encephalopathy and hypersplenism limit the candidacy of 
patients for interferon-based therapies. Pre-transplant 
HCV treatment enthusiasm has also been curbed by the 
lower rates of sustained virologic response in those with 
fibrotic disease compared to those with less severe 
histology. Several advances in HCV therapy have allowed 
incremental progress in overcoming these hurdles. As 
described above, peginterferons have shown better 
efficacy that unmodified interferons in the treatment of 
cirrhotic stage HCV. [2] Additionally, the use of growth 
factors, specifically G-CSF and erythropoietin, has 
allowed more aggressive dosing of interferon and 
ribavirin. [13, 14] Finally, growing experience with 
antiviral therapy in this high-risk group has led to novel 
approaches and increasing success. Table 2 provides 
details on the published results of antiviral therapy in this 
difficult-to-treat population.  
Table 2. Summary of results from interferon-based treatment 
regimens in patients with advanced liver disease 




ETR SVR Dose reduction 
VanThiel 13 1995 5MU/day  30  - -  -  56% 46%  - 
Crippin  15 2002  various 15  85%  - 11.9  33%  - 0% 
Thomas  16 2003 5MU/day  20  67% 80%  10 60% 20%  15% 
Forns 17 2003 3MU/day 
RBV 800 
30  83% 50%  - 30% 20%  63% 
Everson  18 2005  LADR 124 70% 55%  7.4 46% 24%  22% 
 
Early published results with interferon/ribavirin-
based regimens were unfavorable, leading to concern for 
the safety of such an approach. Crippin and colleagues 
randomized end-stage liver disease patients on the 
transplant waiting list to three dose regimens: interferon 
alfa-2b, 1 million units (MU) daily, interferon alfa-2b 3MU 
t.i.w., and interferon alfa-2b 1MU daily with ribavirin 400 
mg PO BID. [15] These very sick patients (CPT mean 11.9) 
were subject to strict eligibility requirements: platelet 
count > 45,000/mL, Hemoglobin > 11 g/dL, and absolute 
neutrophil count (ANC)>1250/mL. Dose reductions or 
study discontinuation were mandated for ANC < 750/mL 
or platelets < 45,000/mL and ANC < 500/mL or platelets 
< 20,000/mL, respectively. Ribavirin dose was decreased 
for hemoglobin < 10 g/dL and discontinued for 
hemoglobin < 8.0 g/dL. Of those patients screened, 47% 
met entry criteria (most excluded for thrombocytopenia) 
of whom 33% (5/15) cleared virus on treatment. Of two 
patients that went to LT, one was a responder, but 
relapsed. Of concern was the safety profile: 20 severe 
adverse drug reactions were reported, including two 
serious infections, one of which led to multi-organ system Int. J. Med. Sci. 2006, 3 
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failure and death. Enrollment was discontinued well short 
of intentions because of these complications. 
Despite this setback, enthusiasm for pre-transplant 
therapy was rekindled by additional studies. Thomas and 
colleagues reported their experience with high-dose 
unmodified interferon monotherapy in 2003. [16] This 
report was similar to a similar protocol used in 1995 by 
the same principal investigator. [13] Of the 20 patients 
who were given interferon alfa-2b, 5MU/day 
subcutaneously, 60% cleared virus on therapy and 20% 
had SVR. Of those that cleared virus, 33% remained non-
viremic after liver transplantation. This regimen, which 
employed G-CSF to maintain ANC > 1500 cells/mL was 
well tolerated, with temporary dose discontinuation in 
3/20 (15%). 
Forns and colleagues used relatively high-dose 
interferon/ribavirin therapy in their cohort of 30 patients 
awaiting transplantation in Spain in an effort to reduce 
viral load at the time of LT. [17] When the investigators 
estimated 4 months remained until transplantation, 
interferon alfa-2b 3MU/day and ribavirin 800 mg/day 
were initiated, with a resulting mean treatment period of 
12 weeks in 30 patients.  The virologic response rate on 
therapy was 30%, with two-thirds of responders 
remaining non-viremic after LT. As in other such trials 
many wait-listed patients did not meet eligibility 
requirements (38%), and side effects were common. 
Despite the use of G-CSF and erythropoietin, dose 
reduction of interferon was required in 60%, while 
ribavirin dose was decreased in 23% of study patients. 
Everson and colleagues offer the largest series to date 
with a unique low accelerating dosage regimen (LADR). 
[18] One hundred twenty four patients were treated with 
unmodified interferon or peginterferon at low initial dose, 
with increases every two weeks toward standard target 
doses. Duration of therapy was intended to be 24 weeks in 
genotypes 2 and 3 and 48 weeks in genotype 1 infection. 
Hematologic inclusion criteria included ANC > 800 
cells/mL, hemoglobin > 10 g/dL and platelets > 
35,000/mL. Growth factors were allowed in the 
management of therapy-induced cytopenias. The 
investigators estimated that “one fourth to one sixth of the 
patients referred to our clinic with advanced liver disease 
were treated with LAD during his period.” End of 
treatment response was seen in 46% while the SVR rate 
was 22%. SVR was associated with non-1 genotype, CPT 
class A, and a complete course of therapy. As expected in 
this very ill set of patients, adverse drug reaction rates 
were relatively common, with two such events potentially 
contributing to patient mortality. Of the 15 patients that 
were virologically negative at the time of transplantation, 
12 remained HCV(-) for at least six months following LT. 
Although the data are mixed on the effectiveness and 
safety of interferon-based therapies in patients with 
decompensated cirrhosis, the demonstrated possibility of 
viral eradication in this group with possible improvement 
in hepatic synthetic function and improved post-
transplant outcome provide an important rationale for 
further studies in this area.  Future work will focus on 
pegylated accelerating dose regimens, the increased use of 
growth factors and non-interferon based antiviral 
therapies. Currently, it is advisable to treat such patients 
only in experienced centers with close monitoring for 
adverse events. [1, 19]  
3.  Research Direction 
The morbidity of recurrent HCV following liver 
transplantation has made pre-transplant antiviral therapy 
a high priority for research. The low accelerating dosage 
regimen of Everson and colleagues has demonstrated 
good efficacy but must be replicated in other cohorts and 
centers. The development of new, non-
immunomodulatory antiviral agents promises to be a 
significant advance in the treatment of this population. 
Ultimately, individualization of the anti-viral regimen 
chosen in each case may lead to better efficacy rates with 
less adverse drug reactions and side-effects. 
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